Pharma Mar SA (ES:PHM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharma Mar SA has successfully recruited 705 patients for its phase III LAGOON clinical trial, which evaluates the efficacy of Zepzelca® (lurbinectedin) in treating small cell lung cancer. This significant milestone reflects the company’s ongoing commitment to expanding treatment options, with preliminary results anticipated in early 2026. The trial aims to assess overall and progression-free survival, contributing to the growing body of research on advanced cancer therapies.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.